Physician profile
Daniel Goldbach
NPI 1447612213
$9,138.06
in general payments reported to CMS, 2019-2025
32 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $1,001 · 2021: $1,203 · 2022: $1,202 · 2023: $1,662 · 2024: $1,569 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,683 · Education: $29.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,683.17 |
| Education | $29.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,562.64 | 2019-2025 | Watchman Flx, Latitude Communicator Power Supply, Watchman Access System |
| Amgen INC. | $1,440.97 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $714.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $612.14 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $568.63 | 2019-2025 | Lifevest |
| Pfizer INC. | $513.34 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $436.33 | 2019-2025 | Wainua, Lokelma, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $384.21 | 2019-2025 | Eliquis, Camzyos |
| Philips North America LLC | $374.95 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions |
| Janssen Pharmaceuticals, INC | $366.42 | 2022-2024 | Xarelto |
| Scpharmaceuticals INC. | $247.78 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $199.33 | 2021-2024 | Verquvo |
| Lantheus Medical Imaging, INC. | $192.11 | 2019-2021 | |
| Novo Nordisk INC | $186.25 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $174.99 | 2021-2023 | Amplatzer Amulet, Confirm Rx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $163.92 | 2022-2025 | Nexletol |
| Medtronic Vascular, INC. | $162.42 | 2020 | |
| Heartflow, INC. | $137.18 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $111.52 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $93.12 | 2022-2025 | Amvuttra, Onpattro |
| Irhythm Technologies, INC. | $76.36 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $75.43 | 2022-2024 | |
| Impulse Dynamics (USA) INC. | $63.68 | 2023-2024 | Optimizer, Optimizer |
| Atricure, INC. | $51.62 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Medtronic, INC. | $50.08 | 2024-2025 | Linq II, Reveal Linq, Tyrx |
| Kiniksa Pharmaceuticals, LTD. | $46.88 | 2022-2023 | Arcalyst |
| Baxter Healthcare | $28.91 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Glaxosmithkline, LLC. | $23.92 | 2025 | Shingrix, Arexvy |
| Edwards Lifesciences Corporation | $20.60 | 2024 | Hemosphere |
| Regeneron Healthcare Solutions, INC. | $20.42 | 2024 | Evkeeza, Praluent |
| Lilly USA, LLC | $18.69 | 2025 | Zepbound |
| Lexicon Pharmaceuticals, INC. | $18.36 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Goldbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.